FIELD: immunology; virology.
SUBSTANCE: there is created an immunobiological agent containing an expression vector based on the genome of a recombinant human adenovirus strain of 26th serotype, in which E1 and E3 regions are deleted, and the ORF6-Ad26 region is replaced by ORF6-Ad5, with an embedded SEQ ID NO: 1 expression cassette. In addition, there is created an immunobiological agent containing an expression vector based on the genome of the recombinant human adenovirus strain of 5th serotype, in which E1 and E3 regions are deleted, with an embedded SEQ ID NO: 1 expression cassette.
EFFECT: group of inventions provides effective induction of the immune response against Lassa virus and prevention of Lassa fever.
3 cl, 2 dwg, 8 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNOBIOLOGICAL AGENT AND METHOD FOR ITS USE FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST VIRUSES SARS-COV-2 VARIANT B.1.617.2 (DELTA) AND SARS-COV-2 VARIANT B.1.1.529 (OMICRON) (VARIANTS) | 2022 |
|
RU2779634C1 |
| DRUG APPLICATION FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2 IN CHILDREN | 2021 |
|
RU2761904C1 |
| AGENT FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-COV-2) IN LIQUID FORM (VERSIONS) | 2021 |
|
RU2743963C1 |
| AGENT FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-COV-2) IN LYOPHILIZED FORM (VERSIONS) | 2021 |
|
RU2743962C1 |
| IMMUNOBIOLOGICAL AGENT AND A METHOD FOR USE THEREOF FOR INDUCING SPECIFIC IMMUNITY TO THE MIDDLE EASTERN RESPIRATORY SYNDROME VIRUS (VERSIONS) | 2018 |
|
RU2709659C1 |
| IMMUNOBIOLOGICAL AGENT FOR INDUCTION OF IMMUNE RESPONSE TO FILOVIRUSES: EBOLAVIRUS AND/OR MARBURGVIRUS, METHOD OF USING IMMUNOBIOLOGICAL AGENT | 2021 |
|
RU2760439C1 |
| Immunobiological agent and method of use thereof for inducing specific immunity against the severe acute respiratory syndrome virus SARS-CoV-2 (embodiments) | 2020 |
|
RU2720614C1 |
| USE OF AGENT FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME SARS-COV-2 FOR POPULATION REVACCINATION (VERSIONS) | 2021 |
|
RU2744444C1 |
| USE OF AGENT FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME SARS-COV-2 FOR POPULATION REVACCINATION IN PEOPLE OVER 60 AND/OR WITH CHRONIC DISEASES (VERSIONS) | 2021 |
|
RU2744442C1 |
| PHARMACEUTICAL AGENT AND METHOD FOR USE THEREOF FOR INDUCING SPECIFIC IMMUNITY TO VIRUS OF SEVERE ACUTE RESPIRATORY SYNDROME SARS-COV-2 (EMBODIMENTS) | 2020 |
|
RU2731342C1 |
